Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors
Conditions
Interventions
E303
Locations
1
United States
Research Site
Fairfax, Virginia, United States
Start Date
March 23, 2026
Primary Completion Date
July 1, 2030
Completion Date
July 1, 2030
Last Updated
April 13, 2026
NCT07360314
NCT07403721
NCT06898450
NCT05719558
NCT07029399
NCT04826341
Lead Sponsor
Samsung Bioepis Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions